儿童与青年常染色体隐性遗传多囊肾病的先进MRI方法
本文综述了面向儿童和青年常染色体隐性遗传多囊肾病(ARPKD)的新兴定量MRI技术。这些多参数定量方法可无创评估肾脏与肝脏的结构和功能改变,有望作为影像生物标志物。跨机构标准化与协调对推动多中心研究和未来治疗试验至关重要。
要点
- ARPKD肾脏表现为弥漫性梭形集合管扩张(微囊肿)并致肾功能进行性下降。
- 患者可伴临床显著的先天性肝纤维化和门静脉高压,阅片需同时关注肝。
- 定量MRI可在多数情况下不使用对比剂、无电离辐射地评估肾肝结构与功能。
核心结论
- 多种新兴定量MRI技术有望作为儿童和青年ARPKD的影像生物标志物,全面表征肾脏和肝脏的结构与功能改变。
- 跨机构持续开发和协调这些定量影像生物标志物对推动多中心研究及未来治疗试验具有关键意义。
研究设计与样本
- 本文为叙述性综述,总结新兴的基于定量MRI的技术在儿童和青年ARPKD中的应用前景。
关键影像表现/征象
- ARPKD肾脏疾病的特征为弥漫性肾脏梭形集合管扩张(微囊肿),导致进行性肾功能障碍。
临床应用与阅片要点
- MRI提供多参数定量评估组织结构和功能的机会,且无电离辐射,许多情况下无需对比剂。
- 阅片时应关注ARPKD相关的肾脏微囊肿改变及先天性肝纤维化、门静脉高压表现。
局限性
- 这些定量影像生物标志物仍需跨机构的持续开发和协调才能用于多中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Autosomal recessive polycystic kidney disease (ARPKD) is a rare, genetic ciliopathy with significant associated morbidity and mortality. ARPKD kidney disease is characterized by diffuse kidney fusiform collecting duct dilatations (microcysts) leading to progressive kidney dysfunction. Patients with ARPKD can also develop clinically-significant congenital hepatic fibrosis and portal hypertension. Despite advances in clinical management, there are currently no disease-modifying therapies approved for ARPKD, and the development of clinical trials has been limited by the lack of sensitive, non-invasive biomarkers capable of detecting early disease progression in both the kidney and liver. MRI provides a unique opportunity to address this gap by offering multiparametric, quantitative assessments of tissue structure and function without ionizing radiation or, in many cases, contrast agents. This review summarizes emerging quantitative MRI-based techniques that show promise as imaging biomarkers for children and young adults with ARPKD. These advanced MRI approaches enable comprehensive characterization of the multi-faceted structural and functional changes in the kidney and liver associated with ARPKD. Continued development and harmonization of these quantitative imaging biomarkers across institutions will be critical for enabling multi-center studies and supporting future therapeutic trials aimed at improving outcomes for children and young adults with ARPKD.
引用
- MacAskill, Smothers, Kretzler, et al. Advanced MRI methods for children and young adults with autosomal recessive polycystic kidney disease (ARPKD) to support future multi-center clinical trials. Pediatr Radiol. 2026. PMID: 42517885. doi:10.1007/s00247-026-06737-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。